... evaluated the effects of multiple antiepileptic drugs using tau aggregation assay systems to determine the effects of antiepileptic agents on tau aggregation, a major neuropathological finding associated with AD. Methods: We evaluated the effects of seven antiepileptic agents on intracellular tau...

...Elias Granadillo; Pongsatorn Paholpak; Mario F. Mendez; Edmond Teng Background/Aims: Prior studies of late-onset Alzheimer disease (AD) have reported that cerebrospinal fluid (CSF) tau levels correlate with hippocampal/medial temporal lobe atrophy. These findings suggest that CSF tau indices in AD...

...M. Degerman Gunnarsson; L. Lannfelt; M. Ingelsson; H. Basun; L. Kilander Objective: Cerebrospinal fluid (CSF) amyloid β 42 (Aβ 42 ), total tau (t-tau) and phosphorylated tau (p-tau) are useful as predictors of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia...

...Mirko Bibl; Brit Mollenhauer; Piotr Lewczuk; Hermann Esselmann; Stefanie Wolf; Markus Otto; Johannes Kornhuber; Eckart Rüther; Jens Wiltfang Background/Aims: We determined cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ) 1–38 , Aβ 1–40 , Aβ 1–42 , total tau and phospho-tau (p-tau...

...Thomas P. Baumann; Hüseyin Duyar; Marc Sollberger; Jens Kuhle; Axel Regeniter; Baltazar Gomez-Mancilla; Klaus Schmidtke; Andreas U. Monsch Objective: Our purpose was to measure Aβ 1–42 , T-tau and P-tau 181 in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA...

...-associated protein tau (MAPT) genes being the most common known causes of familial FTLD. In this study, we investigated 39 patients with FTLD, previously found negative for mutations in PGRN and MAPT , for copy number alterations of these 2 genes. Methods: Gene dosage analysis of PGRN and MAPT was performed...

...Elin S. Blom; Vilmantas Giedraitis; Henrik Zetterberg; Hiroaki Fukumoto; Kaj Blennow; Bradley T. Hyman; Michael C. Irizarry; Lars-Olof Wahlund; Lars Lannfelt; Martin Ingelsson Background/Aims: Increased cerebrospinal fluid (CSF) tau, decreased CSF amyloid-β42 (Aβ42) and the apolipoprotein E gene...

..., apathy and depression were assessed using standardised measures in 32 patients with mild Alzheimer’s disease. Methods: The levels of the 42-amino-acid form of β-amyloid (Aβ 1–42 ), tau and p-tau (phosphorylated at threonine 181) were quantified using the conventional enzyme-linked immunosorbent assay...

...Ignacio Mateo; Pascual Sánchez-Juan; Eloy Rodríguez-Rodríguez; Jon Infante; Carlos Fernández-Viadero; Nicolás Peña; José Berciano; Onofre Combarros Abnormal tau hyperphosphorylation has been suggested as being one of the central events in the development of neurofibrillary tangles, which are one...

... trying to elucidate early events in AD pathogenesis. Aim: To investigate how levels of different amyloid-β (Aβ) peptides, as well as tau and phosphorylated tau, in cerebrospinal fluid (CSF) from children with DS change over time. The first CSF sample was taken at 8 months and the following two samples...

...Edward D. Huey; Nadeem Mirza; Karen T. Putnam; Holly Soares; Gyorgy Csako; James A. Levy; Brittany Copenhaver; Robert M. Cohen; Trey Sunderland Background: Cerebrospinal fluid (CSF) measures of β-amyloid 1–42 and tau differ between patients with Alzheimer’s Disease (AD) and elderly normal controls...

...Ignacio Mateo; Jon Infante; Javier Llorca; Eloy Rodríguez; José Berciano; Onofre Combarros Aberrant phosphorylated tau is the major component of the neurofibrillary tangles in Alzheimer’s disease (AD) brains. Glycogen synthase kinase-3β (GSK-3β) phosphorylates tau protein, and increased GSK-3β...

... (Aβ42), total tau (T-tau) and phosphorylated tau (P-tau). A significant positive correlation between the level of P-tau and the number of symptoms according to the DSM-IV criteria (p = 0.041) and the NINCDS-ADRDA (p = 0.029) was observed (i.e. higher levels were found in cases with more symptoms...

... the possible effects of the CDC2 polymorphism on cerebrospinal fluid (CSF) biomarkers in AD patients. CDC2 genotypes were evaluated in relation to CSF protein levels of total tau, phospho-tau and β-amyloid (1–42) in AD patients and control individuals, and in relation to the amount of senile plaques and NFT...

...Onofre Combarros; Lucía Rodero; Jon Infante; Enrique Palacio; Javier Llorca; Carlos Fernández-Viadero; Nicolás Peña; José Berciano A vigorous controversy exists over whether tau tangles or amyloid-β plaques are the primary cause of neurodegeneration in Alzheimer’s disease (AD), and it is not well...

... and gliosis in the affected cerebral cortex and subcortical nuclei, but only aPiD cases had pyramidal tract degeneration. Immunohistochemical analyses demonstrated that tauopathy with phosphorylated tau accumulation in the Pick bodies in PiD cases, while aPiD cases showed ubiquitinopathy with ubiquitin...

...Katarina Nägga; Johan Gottfries; Kaj Blennow; Jan Marcusson The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and β-amyloid 1–42 (Aβ 1–42 ). An assay for tau phosphorylated at threonine 181 (phospho-tau) has recently been developed. We...

...Magnus Sjögren; Pia Davidsson; Anders Wallin; Ann-Kathrine Granérus; Eva Grundström; Håkan Askmark; Eugeen Vanmechelen; Kaj Blennow Both tau and β-amyloid 42 (Aβ42) have been implicated in Alzheimer’s disease (AD) and tau alone in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS...

...Martin Ingelson; Mari Blomberg; Eirikur Benedikz; Lars-Olof Wahlund; Evert Karlsson; Eugeen Vanmechelen; Lars Lannfelt Tau proteins are central to the neuropathology of Alzheimer’s disease and tau levels in cerebrospinal fluid are elevated in affected individuals. In this study, we investigated...

... based on linkage analysis and has been solidified by the identification of mutations in the tau gene in many families. Mutations affecting the expression or structure of the microtubule binding domain of the tau gene have been found in many large families with chromosome 17q21–22-linked disease...